Antibody–drug conjugates (ADCs) are a promising cancer treatment modality that enables
the selective delivery of highly cytotoxic payloads to tumours. However, realizing the full …

Glycoconjugates are major constituents of mammalian cells that are formed via covalent
conjugation of carbohydrates to other biomolecules like proteins and lipids and often …

Antibody–drug conjugates (ADCs) harness the highly specific targeting capabilities of an
antibody to deliver a cytotoxic payload to specific cell types. They have garnered …

The high selectivity and affinity of antibodies toward their antigens have made them a highly
valuable tool in disease therapy, diagnosis, and basic research. A plethora of chemical and …

Antibody–drug conjugates (ADC) are one of the fastest growing anticancer drugs. This
approach comprises a mAb conjugated to the cytotoxic payload via a chemical linker that …

The immunosensor has been proven a versatile tool to detect various analytes, such as food
contaminants, pathogenic bacteria, antibiotics and biomarkers related to cancer. To fabricate …

Antibody–drug conjugates (ADCs) are one of the fastest growing classes of oncology
therapeutics. After half a century of research, the approvals of brentuximab vedotin (in 2011) …

The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody
conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a …

Antibody–drug conjugates (ADCs) combine the specificity of antibodies with the potency of
small molecules to create targeted drugs. Despite the simplicity of this concept, generation of …

Antibody-based proteins have become an important class of biologic therapeutics, due in
large part to the stability, specificity, and adaptability of the antibody framework. Indeed …